Replies to post #24599 on American Bio Medica Corp (ABMC)

[meluto]

I'm not going into it again(search for my older posts), there is a big difference between big on Covid (and demand for CODX like test) and the demand Healgen test. Does not mean that July was big for ABMC!

https://www.sec.gov/Archives/edgar/data/896747/000165495420010108/abmc_10q.htm

In the above Q2 filing it says(my highlight):

The Covid-19 rapid antibody test is not a diagnostic test. Recently there have been infection surges in and outside the United States. As these infection surges occur, there is a higher demand for diagnostic tests (i.e. PCR’s or antigen tests); although the CDC has indicated that antibody testing can help establish a clinical picture when patients have late complications of COVID-19 illness, such as multisystem inflammatory syndrome in children. We believe that the demand for Covid-19 rapid antibody tests will increase over time as the need for data increases; that is, when testing is used as a means to determine the full impact/extent of the virus, its mortality rate, the length of time antibodies remain in the body and the impact of the antibodies on the virus, as well as a means to monitor the efficacy of vaccines as they are released.